Last update 05 Jul 2025

Gentuximab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Recombinant anti-VEGFR2 chimeric monoclonaly antibody (Changchun Genescience), GenSci-043, GenSci043
+ [1]
Target
Action
antagonists
Mechanism
VEGFR2 antagonists(Vascular endothelial growth factor receptor 2 antagonists)
Inactive Organization-
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
stomach adenocarcinomaPhase 3
China
30 May 2022
Advanced Gastroesophageal Junction AdenocarcinomaPhase 3
China
20 May 2022
Gastroesophageal junction adenocarcinomaPhase 2
China
11 Nov 2019
Gastrooesophageal junction cancerPhase 2
China
01 Aug 2019
Liver metastasesPhase 2
China
01 Aug 2019
EGFR T790M Mutation Positive Non-Small Cell Lung CarcinomaPhase 1
China
02 Apr 2021
metastatic non-small cell lung cancerPhase 1
China
02 Apr 2021
EGFR-mutated non-small Cell Lung CancerPhase 1
China
25 Mar 2021
Malignant Solid NeoplasmPhase 1
China
12 Oct 2017
Metastatic Solid TumorPhase 1
China
11 Oct 2017
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free